Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors

Federico Falchi; Elisa Giacomini; Tiziana Masini; Nicolas Boutard; Lorenza Di Ianni; Marcella Manerba; Fulvia Farabegoli; Lara Rossini; Janet Robertson; Saverio Minucci; Isabella Pallavicini; Giuseppina Di Stefano; Marinella Roberti; Roberto Pellicciari; Andrea Cavalli

doi:10.1021/acschembio.7b00707

Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors

Federico Falchi, Elisa Giacomini, Tiziana Masini, Nicolas Boutard, Lorenza Di Ianni, Marcella Manerba, Fulvia Farabegoli, Lara Rossini, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Marinella Roberti, Roberto Pellicciari, Andrea Cavalli

Research output: Contribution to journal › Article › peer-review

Abstract

In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2-Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.

Original language	English
Pages (from-to)	2491-2497
Number of pages	7
Journal	ACS Chemical Biology
Volume	12
Issue number	10
DOIs	https://doi.org/10.1021/acschembio.7b00707
Publication status	Published - Oct 20 2017

ASJC Scopus subject areas

Biochemistry
Molecular Medicine

Access to Document

10.1021/acschembio.7b00707

Cite this

Falchi, F., Giacomini, E., Masini, T., Boutard, N., Di Ianni, L., Manerba, M., Farabegoli, F., Rossini, L., Robertson, J., Minucci, S., Pallavicini, I., Di Stefano, G., Roberti, M., Pellicciari, R., & Cavalli, A. (2017). Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors. ACS Chemical Biology, 12(10), 2491-2497. https://doi.org/10.1021/acschembio.7b00707

Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors. / Falchi, Federico; Giacomini, Elisa; Masini, Tiziana; Boutard, Nicolas; Di Ianni, Lorenza; Manerba, Marcella; Farabegoli, Fulvia; Rossini, Lara; Robertson, Janet; Minucci, Saverio ; Pallavicini, Isabella; Di Stefano, Giuseppina; Roberti, Marinella; Pellicciari, Roberto; Cavalli, Andrea.

In: ACS Chemical Biology, Vol. 12, No. 10, 20.10.2017, p. 2491-2497.

Research output: Contribution to journal › Article › peer-review

Falchi, F, Giacomini, E, Masini, T, Boutard, N, Di Ianni, L, Manerba, M, Farabegoli, F, Rossini, L, Robertson, J, Minucci, S , Pallavicini, I, Di Stefano, G, Roberti, M, Pellicciari, R & Cavalli, A 2017, 'Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors', ACS Chemical Biology, vol. 12, no. 10, pp. 2491-2497. https://doi.org/10.1021/acschembio.7b00707

Falchi, Federico ; Giacomini, Elisa ; Masini, Tiziana ; Boutard, Nicolas ; Di Ianni, Lorenza ; Manerba, Marcella ; Farabegoli, Fulvia ; Rossini, Lara ; Robertson, Janet ; Minucci, Saverio ; Pallavicini, Isabella ; Di Stefano, Giuseppina ; Roberti, Marinella ; Pellicciari, Roberto ; Cavalli, Andrea. / Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors. In: ACS Chemical Biology. 2017 ; Vol. 12, No. 10. pp. 2491-2497.

@article{ff0b80a9090b4fc6a253f244e181d270,

title = "Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors",

abstract = "In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2-Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.",

author = "Federico Falchi and Elisa Giacomini and Tiziana Masini and Nicolas Boutard and {Di Ianni}, Lorenza and Marcella Manerba and Fulvia Farabegoli and Lara Rossini and Janet Robertson and Saverio Minucci and Isabella Pallavicini and {Di Stefano}, Giuseppina and Marinella Roberti and Roberto Pellicciari and Andrea Cavalli",

year = "2017",

month = oct,

day = "20",

doi = "10.1021/acschembio.7b00707",

language = "English",

volume = "12",

pages = "2491--2497",

journal = "ACS Chemical Biology",

issn = "1554-8929",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors

AU - Falchi, Federico

AU - Giacomini, Elisa

AU - Masini, Tiziana

AU - Boutard, Nicolas

AU - Di Ianni, Lorenza

AU - Manerba, Marcella

AU - Farabegoli, Fulvia

AU - Rossini, Lara

AU - Robertson, Janet

AU - Minucci, Saverio

AU - Pallavicini, Isabella

AU - Di Stefano, Giuseppina

AU - Roberti, Marinella

AU - Pellicciari, Roberto

AU - Cavalli, Andrea

PY - 2017/10/20

Y1 - 2017/10/20

N2 - In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2-Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.

AB - In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2-Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.

UR - http://www.scopus.com/inward/record.url?scp=85031909931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031909931&partnerID=8YFLogxK

U2 - 10.1021/acschembio.7b00707

DO - 10.1021/acschembio.7b00707

M3 - Article

C2 - 28841282

AN - SCOPUS:85031909931

VL - 12

SP - 2491

EP - 2497

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 10

ER -

Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this